Partridge Andrew John 4
4 · Turning Point Therapeutics, Inc. · Filed Jul 14, 2020
Insider Transaction Report
Form 4
Partridge Andrew John
EVP & Chief Commercial Officer
Transactions
- Award
Stock Option (right to buy)
2020-07-13+127,500→ 127,500 totalExercise: $59.94Exp: 2030-07-12→ Common Stock (127,500 underlying) - Award
Common Stock
2020-07-13+21,500→ 21,500 total
Footnotes (2)
- [F1]Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan.
- [F2]25% of the shares vest on July 13, 2021 and 1/48th of the shares vest monthly thereafter over the next three years.